Prof. Xavier Matias-Guiu joins Indivumed’s Onco AI-Med advisory board
Indivumed welcomes Prof. Xavier Matias-Guiu to its Onco AI-Med Adivsory Board, strengthening the alliance’s mission to accelerate individualized cancer treatment worldwide.
Indivumed is proud to announce that Prof. Xavier Matias-Guiu, Head of the Oncological Pathology research group at IRBLleida, Head of the Pathology Department at the Arnau de Vilanova University Hospital, Professor of Pathology at the University of Lleida (UdL) and renowned expert in gynecologic pathology, has joined the Onco AI-Med Advisory Board in October 2025. He has recently been appointed as President of the European Society of Pathology (ESP), as well.
The Onco AI-Med Advisory Board is Indivumed’s global alliance to advance precision oncology through collaboration. This diverse group leverages key expertise in precision medicine, with the collective goal of unlocking the complexities of cancer. Originating from two decades of trusted scientific partnerships, the network brings together leading oncologists and cancer researchers from around the world. Offering guidance and expert counsel to enhance Indivumed’s research and development efforts, the board’s role is crucial in ensuring that our work remains at the forefront of precision oncology. By providing diverse perspectives and sharing ideas, the board helps Indivumed to ensure clinical relevance in the development of novel therapeutic targets.
Prof. Xavier Matias-Guiu emphasizes: “Joining Indivumed’s Onco AI-med Advisory Board is an exciting opportunity to contribute to a truly global effort in precision oncology. By combining our diverse expertise and fostering international collaboration, we can accelerate meaningful progress for cancer patients worldwide.”
Indivumed’s approach combines high-quality multi-omics data with clinical insights from its global network. The Onco AI-Med Advisory Board’s expertise and contribution strengthen our efforts, ensuring the clinical relevance of our research and therapeutics development program. This synergy enables the identification of new therapeutic targets tailored to specific patient cohorts, ensuring that research translates into real-world impact. The global collaboration enhances our ability to drive meaningful advancements in precision oncology.
Hartmut Juhl, CEO and Founder of Indivumed, states: “Innovation is built on collaboration. The Onco AI-Med Advisory Board provides exceptional expertise to our R&D program and plays a crucial role in strengthening translational insights and clinical relevance. By exchanging knowledge and ideas across disciplines, we can achieve our goals faster and deliver meaningful benefits to patients worldwide.”
With experts like Prof. Matias-Guiu and a board of internationally recognized leaders - including Dr. John Marshall as Chairman - Onco AI-Med continues to unlock the complexity of cancer and drive innovation for patients everywhere.